All posts by medical

3 summers of COVID and now monkeypox – you have questions, Vaneet has answers – WUKY

From UK Now:

Monkeypox has exploded into the news recently, with the Centers for Disease Control and Prevention (CDC) closely tracking cases that have been recently reported in several countries that dont normally have monkeypox activity, including the U.S.

University of Kentucky immunology and virology expert Ilhem Messaoudi, Ph.D., answered our questions about the monkeypox virus. Messaoudi, chair of the College of Medicines Department of Microbiology, Immunology, and Molecular Genetics, shares what you need to know about monkeypox including symptoms, risk and treatment.

Q: What is monkeypox?

A: Monkeypox is a disease caused by the monkeypox virus, which is a member of the orthopoxvirus genus within the Poxviridae family. It is in the same genus as variola virus, which causes smallpox.

Is Monkeypox the next COVID? No. Unlike SARS-CoV-2, monkeypox is contagious once the person has developed symptoms, and it is not easily transmitted between individuals. Vaccines against smallpox/monkeypox are available. We also have access to therapeutics in the form of antiviral and vaccinia immune globulins.

Q: What are the symptoms of monkeypox?

A: The incubation period is often seven to 14 days but can be as long as 21 days. Symptoms first start with chills, fever, aches and swollen lymph nodes. This is followed by the appearance of a rash that progresses to blisters.

Q: How does monkeypox spread?

A: Monkeypox is spread via close prolonged contact with body fluids/lesion materials, for example, by caring for or interacting closely with someone exhibiting symptoms, getting bit by an infected animal or manipulating sick animals, or handling contaminated materials. It can be spread via the respiratory route, mucosal route or through broken skin.

Q: As of now, how would you assess the risk for Kentuckians?

A: The risk for Kentuckians is pretty low. However, please note that there is a suspected case in Virginia. Given global travel and increased activities now that several COVID-19 restrictions have been lifted, and the potential of large gatherings at upcoming events, everyone should be vigilant.

Q: How can one best prevent or avoid monkeypox?

A: Practice good hand hygiene, which we should all be very good at by now. If you find yourself in an area where monkeypox has been detected, avoid contact with animals that are sick or found dead. For health care workers caring for monkeypox patients, PPE including respiratory protection and patient isolation are needed.

View post:
3 summers of COVID and now monkeypox - you have questions, Vaneet has answers - WUKY

Antibodies in breast milk help shape infants’ gut bacteria and immunity | Cornell Chronicle – Cornell Chronicle

Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies. Now a new preclinical study by Weill Cornell Medicine investigators shows that one specific set of antibodies that is induced naturally by gut beneficial bacteria can be transferred from mothers to infants through breast milk and help infants defend against infection-induced diarrheal illness.

The study suggests boosting these naturally-produced antibodies in mothers might enhance infants immunity against bacterial pathogens that cause infectious gastrointestinal diseases.

In the study, published June 10 in Science Immunology, the team focused on a class of antibodies called IgG, which help rid the body of infectious bacteria and viruses.Little was known about how IgG antibodies that are naturally induced by gut bacteria influence infant gut immunity. So the investigators used a mouse model to determine how these IgG antibodies are transferred from a mothers blood to her breast milk and how they protect young mice from Citrobacter rodentium (equivalent to pathogenic E. coli in humans) that causes potentially dangerous intestinal infections.

We found that these IgG antibodies were protective against gut infection in the babies and that we could enhance this protection, said senior author Melody Zeng, an assistant professor of immunology in pediatrics within the Department of Pediatrics and a member of the Gale and Ira Drukier Institute for Childrens Research at Weill Cornell Medicine.

Just as antibodies against the SARS-CoV-2 virus are detected in the breast milk of women who had been vaccinated with mRNA vaccines for COVID-19, the researchers sought to confer extra protection against intestinal infections in infants by inducing IgG antibodies that could be transferred this way. They developed a vaccine using a component found in gut bacteria, then immunized female mice with it before they became pregnant.

The same concept, in which vaccination enhances mothers IgG antibody levels and transfers this immunity to her babies, could protect human babies, Zeng said. This strategy could especially benefit premature babies, since they tend to be at much higher risk from diarrheal diseases.

Such infections pose significant dangers for young children in general. Diarrheal illnesses are the second leading cause of death among children under five, according to the World Health Organization.

In their experiments, the researchers, including co-first authors Katherine Sanidad and Mohammed Amir, both postdoctoral associates in the Zeng lab, first demonstrated that when passed to infant mice through breast milk, IgG prevented disease-causing bacteria from attaching themselves to the lining of infants intestines, an early step in infection.

They also studied how IgG interacted with another set of microbes beneficial bacteria that live in the gut to facilitate healthy development of gut bacteria in infants. Scientists are finding that these microbes contribute to the development and function of the immune system. For instance, helpful bacteria train the immune system to recognize their pathogenic relatives.

This study uncovered long-term effects of these protective IgG antibodies too. Mice that never received IgG from their mothers developed abnormal microbial communities within their guts, which led to changes to their immune systems. Specifically, the researchers found an increase in gut immune cells that produce IL-17, a proinflammatory cytokine that is linked to inflammatory diseases. As adults, the IgG-deprived mice were more susceptible to abnormal inflammation associated with inflammatory bowel disorder.

Our findings really underscore the benefits of breastfeeding, both immediately and for the long-term development of the immune system in the offspring, Zeng said.

Melody Zeng is a consultant for Guidepoint.

Wynne Parry is a freelance writer for Weill Cornell Medicine.

Read more from the original source:
Antibodies in breast milk help shape infants' gut bacteria and immunity | Cornell Chronicle - Cornell Chronicle

OSE Immunotherapeutics Appoints its International Scientific Advisory Board – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

NANTES, France, June 09, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the appointment of six leading international experts to its newly formed Scientific Advisory Board (SAB) to guide the Company in its next phases of growth and scientific orientations.

We are proud to have gathered this team of independent world-renowned key-opinion leaders in immunology, immuno-oncology and inflammation, commented Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics. Since OSEs inception, it has been an incredible journey at the forefront of immunology for translating our scientific discoveries into first-in-class innovative immunotherapy treatments against cancers, autoimmune or inflammatory diseases. We will now benefit from their outstanding and highly complementary expertise to further develop our R&D capabilities and nurture the science developed by OSE.

Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics, adds: We are very pleased and honored to bring together experts with such scientific high level and strategic insight in immunology to guide the Company in its scientific orientations. Together with the OSE team, this Board will help addressing novel issues and challenges pertaining to our current and future research to prepare the Companys new phase of growth focused on bringing new entities into our portfolio and advancing our preclinical and diversified first-in-class products in immuno-oncology and immunology & inflammation.

The SAB, chaired by Pr. Wolf-Herv Fridman who will lead the Board's reflections and discussions, will comprise the followings:

Prof. Wolf-Herv Fridman, MD, ChairmanProfessor Emeritus of Immunology at the Universit de Paris Medical School in Paris, FranceDr. Fridmans research focused on the analysis of the tumor microenvironment. Since 2005, his studies have changed the paradigm of host/cancer interactions by demonstrating that the immune contexture, taking into account the functionality, the location and the density of the immune infiltrate in colorectal tumors, is the major prognostic factor for human cancers. He is involved in the development of bioinformatic tools to quantify cells of the tumor microenvironment which are being successfully applied to predict prognosis and immunotherapeutic responses in Renal Cell Cancers, Colorectal Cancers or Sarcomas. One major achievement is the establishment of an immune classification of soft tissue sarcoma tumors that allowed to demonstrate that Tertiary Lymphoid Structures (TLS) and B cell signatures, better than T cells, predicted favorable clinical outcome and therapeutic response to anti-PD- 1 therapy in patients. These findings were recently extended to other cancers treated with immune check-point blockers showing that plasma cells generated inside TLS produce anti-tumor antibodies associated with patients response to immunotherapy. They open the way for novel immune-based tools for efficient prognosis and therapy of cancers.

Dr. Sophie BrouardImmunologist and Doctor in veterinary sciences, Director of Research at the Institut National de la Sant et Recherche Mdicale (INSERM, National Institute for Health and Medical Research) in Nantes, France Dr. Sophie Brouard is Director of Research in the INSERM unit located in Nantes (France) and is working in immunology (auto-immune diseases and transplantation). She is an immunologist interested in fundamental and translational questions on the process of inflammation, chronicity, rejection and tolerance. Previously, she served as Director of the Centaure national RTRS (Rseau Thmatique de Recherche et de Soins) transplantation network in France. Dr. Brouard received the Bronze medal from the French National Center for Scientific Research (CNRS) in 2004, the price from Medicine Academy in 2012, the medal of innovation of the CNRS in 2020 and the Trophe of Academy-Biotech partnership from the Nantes University in 2021. She funded three companies, TclandExpression, Effimune and BioMadvanced.

Dr. Brouard participates and is co-authors of 11 patents. She published around 200 scientific papers (h-factor = 43).

Bernard Malissen, PhDGroup Leader at Centre dImmunologie de Marseille-Luminy and Founding-Director of Center for Immunophenomics, Marseille, FranceDr. Bernard Malissen pioneered the use of gene transfer approaches to dissect the function of Major Histocompatibility Complex (MHC) molecules. He also succeeded reconstructing a full T cell antigen receptor (TCR) complex and demonstrated that the present-day signaling subunits associated with antigen receptors stem from a common primordial building block. He provided the first evidence for chromosomal inversion during TCR gene rearrangements.

His team was also the first to elucidate the atomic structure of an alloreactive TCR in complex with its peptide-MHC ligand, providing a molecular explanation for the basis of transplant rejection and TCR binding-degeneracy. His recent interests extend to dendritic cells and macrophages, leading him to disentangle their functional complexity primarily in the skin. To make sense of the complexity of the signal transduction networks involved in T cell activation, he recently used omic approaches to provide a systems level picture of the TCR signal transduction network and of its tuning by costimulatory and coinhibitory receptors.

Bernard Malissen published 400 scientific papers, (h-factor of 94) and ranked for the last 5 years among the most highly cited researchers in Immunology.

Dr. Myriam Merad, MD, PhDDirector of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC), USDr. Merad is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to human diseases. Dr. Merad identified the tissue resident macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on the development of novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages, Dr. Merad is known for her work on dendritic cells, a group of cells that control adaptive immunity. She identified a new subset of dendritic cells, which is now considered a key target of antiviral and antitumor immunity.

Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to bring immunology discoveries to the clinic. PrIISM integrates immunological research programs with synergistic expertise in biology, medicine, technology, physics, mathematics and computational biology to enhance our understanding of human immunology. She also founded the Human Immune Monitoring Center at Mount Sinai, one of the worlds most sophisticated research centers, which uses cutting-edge single-cell technology to understand the contribution of immune cells to major human diseases or treatment responses.

Dr. Merad has authored more than 200 primary papers and reviews in high profile journals. Her work has been cited several thousand times. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and their contribution to human disease, and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology.She is the President-elect of the International Union of Immunological Societies (IUIS). In 2020, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology.

Prof. Charles N. Serhan, PhD, DScPr. Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School, Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine, USHe is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Womens Hospital and Co-Director of the Brigham Research Institute. Charles received a Bachelor of Science in biochemistry from Stony Brook University followed by a Doctorate in experimental pathology and medical sciences from New York University School of Medicine. He was a visiting scientist and postdoctoral fellow at the Karolinska Institutet, Stockholm with Professor Bengt Samuelsson (Nobel Laurate Medicine 82). In 1987, he joined the faculty at Harvard Medical School and in 1996 received the honorary degree from Harvard University.

Pr. Serhan has experience leading multidisciplinary research teams as PI/PD for several NIH supported Program Project Grants and a P-50 Center Grant. He is currently Program Director of the Program Project entitled Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology (P01-GM095467).

He received several research awards including an NIH MERIT and recent international awards: 2016 Ross Prize in Molecular Medicine, International Eicosanoid Research Foundations 2017 Lifetime Achievement Award, the American Society of Investigative Pathology 2018 Rous Whipple Award, the 2018 British Pharmacology Societys Gaddum International Prize and Award Lecture, and the2019 Honorary Lifetime Award, Society for Leukocyte Biology, for excellence in leukocyte biology research.

His h-index is 172 in google scholar.

Dr. Jennifer Wargo,M.D., M.M.Sc.Professor of Genomic Medicine & Surgical Oncology, UT MD Anderson Cancer Center, HoustonAfter completing her medical degree, she entered surgical residency training at the Massachusetts General Hospital/Harvard Medical School where she became interested in the biology and treatment of cancer. During her training, she completed 2 fellowships in surgical oncology with a focus on immunotherapy for cancer.

Dr. Wargo was recruited to the Division of Surgical Oncology at Massachusetts General Hospital in July 2008 and had an active research laboratory focusing on melanoma tumorigenesis and immunotherapy for cancer. One exciting finding involved data describing the effect of BRAF-targeted therapy on tumor antigen expression in melanoma as a basis for combining targeted therapy and immunotherapy in the treatment of this disease. Dr. Wargo validated those findings in patients treated with BRAF inhibitors. She has continued critical studies to better understand the effects of BRAF inhibition on immune responses in melanoma and established a unique set of serial tumor biopsies and blood samples from patients enrolled in clinical trials on BRAF inhibitors. Through analysis of these samples, she contributed significantly to the world literature regarding resistance mechanisms and the effect of targeted therapy on anti-tumor immunity.

Dr. Wargo was recruited to MD Anderson Cancer Center in September 2013 to continue this work and to build a program to collect serial biopsies in patients with melanoma and other cancers on targeted therapy and immunotherapy, and to better understand responses to therapy and to develop novel strategies to combat resistance.

ABOUT OSE ImmunotherapeuticsOSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:

Immuno-Oncology first-in-class products

Immuno-Inflammation first-in-class products

CoVepiT: a prophylactic second-generation vaccine activating cytotoxic T lymphocytes against COVID-19, developed using optimized epitopes from SARS-CoV2 viral proteins, epitopes non impacted by multi-variants. Shows good tolerance and very good level of T cell immune response. In clinical testing, a long-term memory response was confirmed at 6 months.

Click and follow us on Twitter and LinkedInhttps://twitter.com/OSEIMMUNOhttps://www.linkedin.com/company/10929673

Contacts

Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as expect, anticipate, believe, target, plan, or estimate, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2022, including the annual financial report for the fiscal year 2021, available on the OSE Immunotherapeutics website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Excerpt from:
OSE Immunotherapeutics Appoints its International Scientific Advisory Board - StreetInsider.com

22pc of people tested for Covid-19 are positive as a ‘return to normal’ sees cases rise – Independent.ie

Twenty-two percent of people tested for Covid-19 are positive as cases are rising, an immunology expert has said.

rofessor of Experimental Immunology at Trinity College Dublin Kingston Mills, said the fact that people are back to normal has contributed to a rise in cases.

"The number of cases has risen here, but its not just in Ireland.In the UK, Portugal and Germany, there has been a risein the past couple of weeks, he said on RT Radio 1s This Week.

"This is really on the back of the variants BA.4, BA.5, theseare sub-variants of Omicron, which are distinct from the original Omicron, they have mutated further. They are moretransmissible.

Mr Mills also pointed to the fact that people are now back to normal, and there's no social distancing, no mask-wearing.

There is a lot of contact,a lot of hospitality, so all of that is contributing to the rising case numbers.

He pointed out that the numbers in hospital are rising, so that does suggest that the case numbers are rising.

As of 8am, there were 397 people in hospital with Covid-19, this is an increase of 37 from yesterdays statistics.

The positivity rate of those that are tested has gone up from16 to 22pc, ProfMills said.

"So 22pc of all people that are tested are turning out to be positive, andthats an indication that we are getting an increase in the number of cases, as well as the number ofhospitalisations.

Omicron and its sub-variants largely infect theupper respiratory tract and they dont go as much into the lung, unless somebody has an underlying lung condition.

Prof Mills said that for a normal, healthy person this is not a very serious disease, but for people who are older, or people with underlying medical conditions or on some immunotherapy that might make their immune system suppressed, it is still a concern.

And these are the ones that are vulnerable now. It's important that if they havent been vaccinated with a fourth dose, or have recently had Covid, they should get a booster vaccine."

Prof Mills saidhe knew of a lot of older people, and people with underlying health conditions who havent yet had Covid who are still worried about getting it, because they feel that they may end up in hospital if they do get it and that is a big concern.

"And that is the big worry in this with increasing case numbers, it isinevitable that some will end up in hospital.

For the normal healthy person, its not a big deal getting this infection, in fact getting the infection now, especially if youve had the vaccine, three doses of the vaccine, will add to your immunity and probably prevent you from getting re-infected at this stage.

But the trouble is, even getting infected with the original Omicron is not now having as much protection against reinfection with B.A4 and B.A5 and thats the worry about this virus, it keeps changing and if it changes again, that will make it even more difficult for the vaccines to work.But the good news is the vaccines do prevent severe disease."

Prof Mills said those who have had their vaccine doses are in a better place than those who have not been vaccinated.

There is a lot of concern for those who are not vaccinated in the older age group or with underlying medical conditions, he said.

The rest is here:
22pc of people tested for Covid-19 are positive as a 'return to normal' sees cases rise - Independent.ie

Battle of the Vaccines: Inhaled is Better than Nasal Sprays – Laboratory Equipment

Michael D'Agostino demonstrates the aerosol delivery method, which in this study was done on animal models. Credit: McMaster University

McMaster University scientists who compared respiratory vaccine-delivery systems have confirmed that inhaled aerosol vaccines provide far better protection and stronger immunity than nasal sprays.

While nasal sprays reach primarily the nose and throat, inhaled aerosols bypass the nasal passage and deliver vaccine droplets deep in the airway, where they can induce a broad protective immune response, the researchers report.

For the study, published online in the journalFrontiers in Immunology, the researchers used a tuberculosis vaccine to compare delivery methods by measuring the distribution of droplets, immune responses and potency in animals.

When the vaccine was delivered directly into the lungs it stimulated stronger immune responses, providing much better protection from TB.

Infections in the upper respiratory tract tend to be non-severe. In the context of infections caused by viruses like influenza or SARS-CoV-2, it tends to be when the virus gets deep into the lung that it makes you really sick, explains Matthew Miller, a co-author of the study who holds the Canada Research Chair in Viral Pandemics at McMaster University.

The immune response you generate when you deliver the vaccine deep into the lung is much stronger than when you only deposit that material in the nose and throat because of the anatomy and nature of the tissue and the immune cells that are available to respond are very different, says Miller, who is alsoan investigator with Canadas Global Nexus for Pandemics & Biological Threats, which is based at McMaster.

This study for the first time provides strong preclinical evidence to support the development of inhaled aerosol delivery over nasal spray for human vaccination against respiratory infections including TB, COVID-19 and influenza, says Zhou Xing, co-investigator of the study and a professor at the McMaster Immunology Research Centre and Department of Medicine.

More than 6.3 million have people died during the COVID-19 pandemic, and respiratory infections remain a significant cause of illness and death throughout the world, driving an urgent and renewed worldwide effort to develop vaccines that can be delivered directly to the mucous lining of the respiratory tract.

Scientists at McMaster, who have developed a unique inhaled form of COVID vaccine,believe this deep-delivery method offers the best defence against the current and future pandemics.

APhase 1 clinical trialis currently under way to evaluate the inhaled aerosol vaccine in healthy adults who had previously received two or three doses ofan injected COVID mRNA vaccine.

Nasal mist flu vaccines have been shown to be highly effective in children, but much less effective in adults, leaving injectable flu vaccines as the most popular choice for seasonal flu vaccinations.

Previous research by the McMaster team has shownthat in addition to being needle-free and painless, an inhaled vaccine is so efficient at targeting the lungs and upper airways that it can achieve maximum protection with a much smaller dose than injected vaccines.

Republished courtesy of McMaster University.

Read more from the original source:
Battle of the Vaccines: Inhaled is Better than Nasal Sprays - Laboratory Equipment

The origin of monkeypox outbreaks in non-endemic nations – News-Medical.Net

In a recent review posted to the OSF* preprint server, the author explained the causes of the mysterious origin of the recent monkeypox outbreaks in non-endemic nations outside Africa.

Monkeypox cases are on the rise in several non-endemic nations worldwide despite the absence of travel links and connected clusters with Africa. Despite the worldwide prevalence, the causes of the origin of monkeypox beyond the African continent are unclear. If the much more fatal Ebola virus emerges similarly, serious consequences for human health could be expected, and therefore, the origin of the mysterious monkeypox outbreaks must be understood.

In the present review, researchers reported on the causes of the origin of monkeypox outbreaks in several non-endemic nations across the globe.

The recent monkeypox outbreaks cannot be explained based on logical conclusions of data obtained by experimental analysis but by illustrating the reality and making logical deductions only to obtain consequences that must agree with experiences.

The effects of causative pathogens that allow immune pathways to protect organisms from acquiring infections by those pathogens are not dependent on the exclusive nature of a certain pathogen but on the immunological nature in which the pathogenic effects are shared with sterile cause effects.

Immunological mechanisms that decrease pathogen load among animals may not necessarily decrease the disease severity or render the diseases asymptomatic. This is supported by lower severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) loads reported in few severe SARS-CoV-2 infections compared to asymptomatic and mild SARS-CoV-2 infections. The findings indicate that the severity of a disease depends on the hyper-inflammatory state instead of the direct effects of pathogen toxicity.

Therefore, outbreaks of infections that have been considered asymptomatic do not necessarily require pathogenic transmission but instead the disappearance of several conditions that allow immunological mechanisms to consider them asymptomatic without eliminating the disease causes.

Different diseases with different causes but with pathological effects of identical immunology may present with different manifestations in the absence of the pathogen (monkeypox virus). Different causes with effects of the same immunological nature manifest concomitantly in monkeypox cases and are already present in individuals in non-endemic nations. Therefore, monkeypox outbreaks have appeared in regions beyond the African continent, despite the absence of travel links and connected clusters with Africa.

Researchers have made relentless efforts to characterize the genetic basis for the widespread global prevalence of the monkeypox in the central parts of Africa compared to the western regions of Africa. It has been assumed that the pathogens responsible for central African outbreaks have higher transmissibility and virulence than those responsible for the outbreaks in West Africa.

However, a common observation among all monkeypox case clusters is exposure to factors facilitating the disappearance of conditions that allow immunological mechanisms to render monkeypox asymptomatic without eliminating etiological factors of the same immunological nature. Therefore, the origin of monkeypox in non-endemic zones is not dependent on the transmissibility or virulence of the monkeypox virus but on the disappearance (and reappearance) of conditions in response to which the manifestations of monkeypox appear.

Furthermore, the manifestations of an infection linked to a particular pathogenic organism are as diverse as the disappearance of conditions that allow the immune system and different driving factors of the same immunology to give rise to concomitant asymptomatic infections. The severity of the manifestations is comparable to those of infections sharing the same immunology, independent of the transmissibility and virulence of the pathogenic organism.

The manifestations linked to pathogens would cause catastrophic effects in individuals even in the absence of the causative pathogen if factors cause fading away of conditions that allow infections with the same immunology to be considered asymptomatic. Such infections could spread extensively within a short period.

Based on the findings, further research must explore the immunological nature of the more fatal Ebola virus infections and identify different diseases that share similar immunology as that of Ebola infection, respectively.

Such an approach would be more beneficial in preventing the probable catastrophic effects of Ebola infections instead of investigating the genetic basis of Ebola virus infections or the transmissibility and virulence of the Ebola virus. In addition, factors that allow immunological mechanisms to consider Ebola virus infections to be asymptomatic must be determined.

OSF publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Read this article:
The origin of monkeypox outbreaks in non-endemic nations - News-Medical.Net

University of Utah Health Biochemist Matt Miller Named Pew Scholar – University of Utah Health Care

Jun 14, 2022 8:00 AM

Matthew Miller, Ph.D., an assistant professor of biochemistry at University of Utah Health, was named as a 2022 Pew Scholar for his exploration of the cellular machines that help accurately divide and separate chromosomes during cell division. This work is critical as even the smallest errors in this process can have harmful consequences, including birth defects, miscarriages, and cancer.

Miller is one of 22 scientists nationwide to receive the honor from the Pew Charitable Trusts. The Pew Scholars Program in the Biomedical Sciences provides funding to early-career investigators of outstanding promise in science that is relevant to the advancement of human health.

Millers research focuses on a key phase of cell division, or mitosis, when protein-based machines called kinetochores help chromosomes correctly maneuver between parent and newly forming daughter cells. This process ensures that each cell receives a complete set of accurately replicated chromosomes.

Better understanding of how kinetochores work could lead to the development of genetic interventions or other treatments to reduce the risk of these disorders, Miller says.

Matt Miller is studying a truly fascinating and red-hot area of research, says Wes Sundquist, Ph.D., a former Pew Scholar and chair of the Department of Biochemistry at the University of Utah Health. To address this problem, Matt uses an amazingmulti-disciplinary combination of biochemistry, biophysics, genetics, and cell biology for which he is almost uniquely qualified owing to his wonderful breadth, insight, and creativity.

Understanding the process of chromosome separation during mitosis is a difficult challenge, according to Miller. Thats because of its dynamic nature and the inability to precisely replicate the physical forces that regulate these activities in cells.

To overcome this difficulty, Miller and his colleagues purify the protein machines involved and have developed techniques which allow them to reestablish their complex activities outside of a cell. This allows the researchers to experimentally control things such as applied physical force and ultimately understand how these factors carry out this process so reliably.

Kinetochores are incredible protein machines, Miller says. They move chromosomes within an ever-changing environment and are signaling hubs that help regulate the cell cycle. Biologists have been fascinated with this process for more than 100 years, yet we still dont know how kinetochores achieve their remarkable feats.

In fact, according to Miller, scientists still dont have a complete parts list for the inner workings of kinetochores. Its like knowing that an internal combustion engine makes a car run but not understanding that under the hood it is a collection of pistons, spark plugs, and other vital moving parts, he says.

Despite this, Miller and his colleagues are unraveling several key aspects of kinetochores and their role in cell division.

During cell division, the cells genetic information, or DNA, is packaged into structures known as chromosomes, which need to be copied and then partitioned equally between resulting daughter cells. To facilitate this process, kinetochores assemble on chromosomes and attach themselves to the mitotic spindle, a molecular machine that forms thin, thread-like strands called microtubules. Once they do this, the duplicated chromosomes can move to opposite ends of the parent cell in preparation for cell division.

If kinetochores dont do their job correctly, then the chromosomes wont divide evenly, and one cell could end up with too many or too few of them. As a result, harmful imbalances and mutations can occur, Miller says.

Fortunately, these types of errors are rare. So what keeps the chromosomes attached to the right microtubules? It all boils down to tension, Miller says.

To accurately segregate replicated chromosomes to daughter cells, the chromosome must attach to microtubules from opposite sides of the cell. This pulling from opposite sides generates tension, telling the cell it has the correct attachment configuration and can proceed with cell division. Miller and colleagues recently discovered that kinetochores have an intrinsic mechanism that senses this tension. It acts, Miller says, like a childs finger trap, a simple puzzle that traps fingers in both ends of a small cylinder woven from bamboo. The harder a person tries to pull their fingers out, the tighter the device gets.

In much the same way, the tension created by the force of opposing microtubule pulling keeps the chromosomes aligned properly. When the kinetochores sense the right amount of tension, they give the go-ahead signal and then move each of their chromosomes to opposite sides of the parent cell, enabling accurate cell division.

Using an array of cutting-edge tools in biochemistry, biophysics, and gene editing, Miller hopes to determine which parts of the protein machines are responsible forchromosomal attachment and segregation.

We will then reconstitute the activities of these protein machines in a test tube to discover the mechanisms these protein machines use to carry out this process, Miller says. This work could lead to novel strategies for reducing the chromosomal segregation defects that give rise to many human diseases, including cancer and developmental disorders such as Down syndrome.

The 2022 class of Pew scholarsall early-career, junior facultywill receive four years of funding to explore some of the most pressing questions in health and medicine. They were chosen from 197 applicants nominated by leading academic institutions and researchers across the United States.

####

Research News Biochemistry Pew Scholar

Read the rest here:
University of Utah Health Biochemist Matt Miller Named Pew Scholar - University of Utah Health Care

Online Biochemistry Course | MCAT or Med School Prep | Arizona Online

University of Arizona Privacy Statement

View the University of Arizona's Privacy Statement

View the University of Arizonas electronic privacy policy

The University of Arizona Online website collects anonymous visitor data using Google Analytics. We utilize first- and third-party cookies to measure website and campaign effectiveness, but no personal information is collected automatically.

Remarketing with Google AnalyticsGoogle Display Network Impression ReportingDoubleClick Platform integrationsGoogle Analytics Demographics and Interest Reporting

More information about Googles user data security policy for Google AnalyticsYou can opt out of Google Analytics tracking by installing this browser extension

By entering and submitting information in any Request for Information form on the University of Arizona Online website, you consent to being contacted via phone, email, text message and/or pre-recorded message by the University of Arizona Online and its affiliates.

See the original post here:
Online Biochemistry Course | MCAT or Med School Prep | Arizona Online

Caltech Professor of Chemistry and Biochemistry Decodes a Key Part of the Cell, Atom by Atom Pasadena Now – Pasadena Now

Credit: Valerie Altounian

Whatever you are doing, whether it is driving a car, going for a jog, or even at your laziest, eating chips and watching TV on the couch, there is an entire suite of molecular machinery inside each of your cells hard at work. That machinery, far too small to see with the naked eye or even with many microscopes, creates energy for the cell, manufactures its proteins, makes copies of its DNA, and much more.

Among those pieces of machinery, and one of the most complex, is something known as the nuclear pore complex (NPC). The NPC, which is made of more than 1,000 individual proteins, is an incredibly discriminating gatekeeper for the cells nucleus, the membrane-bound region inside a cell that holds that cells genetic material. Anything going in or out of the nucleus has to pass through the NPC on its way.

The NPCs role as a gatekeeper of the nucleus means it is vital for the operations of the cell. Within the nucleus, DNA, the cells permanent genetic code, is copied into RNA. That RNA is then carried out of the nucleus so it can be used to manufacture the proteins the cell needs. The NPC ensures the nucleus gets the materials it needs for synthesizing RNA, while also protecting the DNA from the harsh environment outside the nucleusandenabling the RNA to leave the nucleus after it has been made.

Its a little like an airplane hangar where you can repair 747s, and the door opens to let the 747 come in, but theres a person standing there who can keep a single marble from getting out while the doors are open, says CaltechsAndr Hoelz, professor of chemistry and biochemistry and a Faculty Scholar of the Howard Hughes Medical Institute. For more than two decades, Hoelz has been studying and deciphering the structure of the NPC in relation to its function. Over the years, he has steadily chipped away at its secrets, unraveling thempiecebypiecebypiecebypiece.

The implications of this research are potentially huge. Not only is the NPC central to the operations of the cell, it is also involved in many diseases. Mutations in the NPC are responsible for some incurable cancers, for neurodegenerative and autoimmune diseases such as amyotrophic lateral sclerosis (ALS) and acute necrotizing encephalopathy, and for heart conditions including atrial fibrillation and early sudden cardiac death. Additionally, many viruses, including the one responsible for COVID-19, target and shutdown the NPC during the course of their lifecycles.

Now, in a pair of papers published in the journalScience,Hoelz and his research team describe two important breakthroughs: the determination of the structure of the outer face of the NPC and the elucidation of the mechanism by which special proteins act like a molecular glue to hold the NPC together.

In their paper titled Architecture of the cytoplasmic face of the nuclear pore, Hoelz and his research team describe how they mapped the structure of the side of the NPC that faces outward from the nucleus and into the cells cytoplasm. To do this, they had to solve the equivalent of a very tiny 3-D jigsaw puzzle, using imaging techniques such as electron microscopy and X-ray crystallography on each puzzle piece.

Stefan Petrovic, a graduate student in biochemistry and molecular biophysics and one of the co-first authors of the papers, says the process began withEscherichia colibacteria (a strain of bacteria commonly used in labs) that were genetically engineered to produce the proteins that make up the human NPC.

If you walk into the lab, you can see this giant wall of flasks in which cultures are growing, Petrovic says. We express each individual protein inE. colicells, break those cells open, and chemically purify each protein component.

Once that purificationwhich can require as much as 1,500 liters of bacterial culture to get enough material for a single experimentwas complete, the research team began to painstakingly test how the pieces of the NPC fit together.

George Mobbs, a senior postdoctoral scholar research associate in chemistry and another co- first author of the paper, says the assembly happened in a stepwise fashion; rather than pouring all the proteins together into a test tube at the same time, the researchers tested pairs of proteins to see which ones would fit together, like two puzzle pieces. If a pair was found that fit together, the researchers would then test the two now-combined proteins against a third protein until they found one that fit with that pair, and then the resulting three-piece structure was tested against other proteins, and so on. Working their way through the proteins in this way eventually produced the final result of their paper: a 16-protein wedge that is repeated eight times, like slices of a pizza, to form the face of the NPC.

We reported the first complete structure of the entire cytoplasmic face of the human NPC, along with rigorous validation, instead of reporting a series of incremental advances of fragments or portions based on partial, incomplete, or low-resolution observation, says Si Nie, postdoctoral scholar research associate in chemistry and also a co-first author of the paper. We decided to patiently wait until we had acquired all necessary data, reporting a humungous amount of new information.

Their work complemented research conducted by Martin Beck of the Max Planck Institute of Biophysics in Frankfurt, Germany, whose team used cryo-electron tomography to generate a map that provided the contours of a puzzle into which the researchers had to place the pieces. To accelerate the completion of the puzzle of the human NPC structure, Hoelz and Beck exchanged data more than two years ago and then independently built structures of the entire NPC. The substantially improved Beck map showed much more clearly where each piece of the NPCfor which we determined the atomic structureshad to be placed, akin to a wooden frame that defines the edge of a puzzle, Hoelz says.

The experimentally determined structures of the NPC pieces from the Hoelz group served to validate the modeling by the Beck group. We placed the structures into the map independently, using different approaches, but the final results completely agreed. It was very satisfying to see that, Petrovic says.

We built a framework on which a lot of experiments can now be done, says Christopher Bley, a senior postdoctoral scholar research associate in chemistry and also co-first author. We have this composite structure now, and it enables and informs future experiments on NPC function, or even diseases. There are a lot of mutations in the NPC that are associated with terrible diseases, and knowing where they are in the structure and how they come together can help design the next set of experiments to try and answer the questions of what these mutations are doing.

This elegant arrangement of spaghetti noodles

In the other paper, titled Architecture of the linker-scaffold in the nuclear pore, the research team describes how it determined the entire structure of what is known as the NPCs linker-scaffoldthe collection of proteins that help hold the NPC together while also providing it with the flexibility it needs to open and close and to adjust itself to fit the molecules that pass through.

Hoelz likens the NPC to something built out of Lego bricks that fit together without locking together and are instead lashed together by rubber bands that keep them mostly in place while still allowing them to move around a bit.

I call these unstructured glue pieces the dark matter of the pore,' Hoelz says. This elegant arrangement of spaghetti noodles holds everything together.

The process for characterizing the structure of the linker-scaffold was much the same as the process used to characterize the other parts of the NPC. The team manufactured and purified large amounts of the many types linker and scaffold proteins, used a variety of biochemical experiments and imaging techniques to examine individual interactions, and tested them piece by piece to see how they fit together in the intact NPC.

To check their work, they introduced mutations into the genes that code for each of those linker proteins in a living cell. Since they knew how those mutations would change the chemical properties and shape of a specific linker protein, making it defective, they could predict what would happen to the structure of the cells NPCs when those defective proteins were introduced. If the cells NPCs were functionally and structurally defective in the way they expected, they knew they had the correct arrangement of the linker proteins.

A cell is much more complicated than the simple system we create in a test tube, so it is necessary to verify that results obtained from in vitro experiments hold up in vivo, Petrovic says.

The assembly of the NPCs outer face also helped solve a longtime mystery about the nuclear envelope, the double membrane system that surrounds the nucleus. Like the membrane of the cell within which the nucleus resides, the nuclear membrane is not perfectly smooth. Rather, it is studded with molecules called integral membrane proteins (IMPs) that serve in a variety of roles, including acting as receptors and helping to catalyze biochemical reactions.

Although IMPs can be found on both the inner and outer sides of the nuclear envelope, it had been unclear how they actually traveled from one side to the other. Indeed, because IMPs are stuck inside of the membrane, they cannot just glide through the central transport channel of the NPC as do free-floating molecules.

Once Hoelzs team understood the structure of the NPCs linker-scaffold, they realized that it allows for the formation of little gutters around its outside edge that allow the IMPs to slip past the NPC from one side of the nuclear envelope to the other while always staying embedded in the membrane itself.

It explains a lot of things that have been enigmatic in the field. I am very happy to see that the central transport channel indeed has the ability to dilate and form lateral gates for these IMPs, as we had originally proposed more than a decade ago, Hoelz says.

Taken together, the findings of the two papers represent a leap forward in scientists understanding of how the human NPC is built and how it works. The teams discoveries open the door for much more research. Having determined its structure, we can now focus on working out the molecular bases for the NPCs functions, such as how mRNA gets exported and the underlying causes for the many NPC-associated diseases with the goal of developing novel therapies, Hoelz says.

The papers describing the work appear in the June 10 issue of the journalScience.

Additional co-authors of the paper, Architecture of the cytoplasmic face of the nuclear pore, are Anna T. Gres; now of Worldwide Clinical Trials; Xiaoyu Liu, now of UCLA; Sho Harvey, a former grad student in Hoelzs lab; Ferdinand M. Huber, now of Odyssey Therapeutics; Daniel H. Lin, now of the Whitehead Institute for Biomedical Research; Bonnie Brown, a former research technician in Hoelzs lab; Aaron W. Tang, a former research technician in Hoelzs lab; Emily J. Rundlet, now of St. Jude Childrens Research Hospital and Weill Cornell Medicine; Ana R. Correia, now of Amgen; Taylor A. Stevens, graduate student in biochemistry and molecular biophysics; Claudia A. Jette, graduate student in biochemistry and molecular biophysics; Alina Patke, research assistant professor of biology; Somnath Mukherjee and Anthony A. Kossiakoff of the University of Chicago; Shane Chen, Saroj G. Regmi, and Mary Dasso of the National Institute of Child Health and Human Development; and Alexander F. Palazzo of the University of Toronto.

Additional co-authors of the paper, Architecture of the linker-scaffold in the nuclear pore, are Dipanjan Samanta, postdoctoral scholar fellowship trainee in chemical engineering; Thibaud Perriches, now of Care Partners; Christopher J. Bley; Karsten Thierbach; now of Odyssey Therapeutics; Bonnie Brown, Si Nie, George W. Mobbs, Taylor A. Stevens, Xiaoyu Liu, now of UCLA; Giovani Pinton Tomaleri, graduate student in biochemistry and molecular biophysics; and Lucas Schaus, graduate student in biochemistry and molecular biophysics.

Funding for the research was provided by the National Institutes of Health, the Howard Hughes Medical Institute, and the Heritage Medical Research Institute.

Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m.

See the original post here:
Caltech Professor of Chemistry and Biochemistry Decodes a Key Part of the Cell, Atom by Atom Pasadena Now - Pasadena Now

New cryo-electron microscopy centers help UW researchers uncover mysteries of life – University of Wisconsin-Madison

At the Steenbock Symposium on June 7 and 8, 2022, the University of WisconsinMadison Department of Biochemistry opened its doors in celebration of two new research centers that bring to campus advanced biomolecular imaging technology called cryo-electron microscopy.

The technology allows scientists to capture detailed information about the smallest components of living cells to understand everything from more effective drug development to how viruses infect cells. It relies on ultra-cold temperatures during biomolecular specimen preservation and imaging and requires the right combination of expertise and highly specialized equipment.

The UWMadison Cryo-Electron Microscopy Research Center and the NIH-sponsored Midwest Center for Cryo-Electron Tomography represent a continuation of UWMadisons long history of contributions to structural biology. The event featured tours of the centers and scientific talks and posters about cryo-EM.

Both centers provide instrumentation, training, technical assistance and support to UWMadison researchers, as well as access to cryo-EM. The centers are also open to other universities and to private industry.

1 Thomas Anderson, a cellular and molecular biology graduate student working in the lab of biochemistry professor Robert Kirchdoerfer, and Anil Kumar, a research specialist in the cryo-EM centers, explain the inner workings of the Titan Krios cryo-electron microscope to their tour group at the Cryo-Electron Microscopy Research Center. Photo by Michael P. King/UW-Madison CALS

2 Industry and campus partnerships are critical to the centers' construction and operation. Zoltan Metlagel, a senior applications engineer at ThermoFisher Scientific, shared his knowledge about tomographic imaging alongside Parrell during one of five interactive workshops held during the open house. Photo by Michael P. King/UW-Madison CALS

3 Joseph Kim, a graduate student in the chemistry department, leads scientists through one of five interactive workshops held during the open house. Dedicated on-site training by center users and staff is available to scientists across campus and beyond. Photo by Michael P. King/UW-Madison CALS

4 Postdoctoral researcher Daniel Parrell explains how to use cryo-electron tomography data to produce an image known as a 3D tomogram. The montage shows biological structures in a thin layer of human cells and was collected using remote access capabilities and a focused ion beam. Remote training and operation of equipment are both features of the new centers. Photo by Michael P. King/UW-Madison CALS

5 Biochemistry professor and Morgridge Institute for Research investigator Elizabeth Wright directs the UWMadison Cryo-Electron Microscopy Research Center, led by a coalition of campus partners, and the NIH-sponsored Midwest Center for Cryo-Electron Tomography. Photo by Robin Davies

6 Open house attendees learned what can be achieved with cryo-EM during scientific talks and poster sessions held in the Discovery Building. Approximately 200 people attended the open house in-person, while another 200 viewed talks and workshops online. Photo by Robin Davies

Read more from the original source:
New cryo-electron microscopy centers help UW researchers uncover mysteries of life - University of Wisconsin-Madison